Amgen, Cytokinetics Checked With Payers Before Taking Omecamtiv Into Phase III

Partnered on chronic heart failure drug omecamtiv mecarbil, Amgen and Cytokinetics took months to design a Phase III trial that would address the needs and concerns of both payers and clinicians.